



Disclaimer

This presentation was prepared by NewMed Energy Limited Partnership (the "Partnership") and is given to you only for the provision of concise information for the sake of convenience and may not be copied or distributed to any other person. The Data and information included in this presentation should not be interpreted as advice and should not be relied on for any purpose. Such data and information should not be copied or used except as expressly permitted in writing.

This presentation does not purport to be comprehensive or to contain any and all information which might be relevant in connection with the making of a decision on an investment in securities of the Partnership.

No explicit or implicit representation or undertaking is given by any person regarding the accuracy or integrity of any information included in this presentation. In particular, no representation or undertaking is given regarding the realization or reasonableness of any forecasts regarding the future chances of the Partnership.

To obtain a full picture of the activities of the Partnership and the risks entailed thereby, see the full immediate and periodic reports filed by the Partnership with the Israel Securities Authority and the Tel Aviv Stock Exchange Ltd., including warnings regarding forward-looking information, as defined in the Securities Law, 5728-1968, included therein. The forward-looking information in the presentation may not materialize, in whole or in part, or may materialize differently than expected, or may be affected by factors that cannot be assessed in advance.

For the avoidance of doubt, it is clarified that the Partnership do not undertake to update and/or modify the information included in the presentation to reflect events and/or circumstances occurring after the date of preparation of the presentation.

This presentation is not an offer or invitation to buy or subscribe for any securities. This presentation and anything contained herein are not a basis for any contract or undertaking and are not to be relied upon in such context. The information provided in the presentation is not a basis for the making of any investment decision, nor a recommendation or an opinion, nor a substitute for the discretion of a potential investor.




Key Highlights

- **Record Sales in quarter** average production in quarter c. 1,100,000 MMbtu/d
- Record daily production output—1,274,000 MMbtu/d (12/03/2022)
- **Record export from Leviathan** 1.83 BCM (c. 65,800,000 MMbtu)
- □ Leviathan 8 drilling operations 5th producing well in Leviathan
- ☐ First export through FAJR to Egyptian market Meanwhile Ongoing work at INGL for the increased capacity to Ashkelon
- Aphrodite updating and optimizing the development plan and preparing to drill the A-3 well.
- Dividend & Buy Back




Key First Quarter Financial Metrics (\$mm)






Change in Net Profit (\$mm)






Production Summary

ВСМ	Israel	Egypt	Jordan	Total
1Q/2022	0.9	1.1	0.7	2.7
Average Price (\$/mmbtu)				5.57
1Q/2021	1.2	0.8	0.7	2.7
Average Price (\$/mmbtu)				4.92





Regional Connectivity Update





Leviathan 8 & Aphrodite Development

Leviathan 8

- Leviathan-8, the 5th production well in the field, was spud on April 4th
- □ Drilling operations are progressing as scheduled on time and on budget and expected to end in a few weeks.

Aphrodite Development

- The partners are working with the Government of Cyprus to update the development plan - integrate the development with existing facilities and / or development plans of adjacent properties.
- The partners are also planning to carry out the A3 drilling well, in a way that will be used as a production well, as part of the reservoir's overall development plan.
- Accordingly, the partners adopted a discission regarding engagement with a drillship for the purpose of carrying out the A3 well.





ESG Update

- Implementing NewMed Alternative Energies Strategy:
 - ☐ Multiple examinations of new projects in the field of carbon neutral energy to meet long term commitments.
 - Advancing international cooperation on Alternative Energy activity
- Promoting transparency and working inline with the GRI guidance:
 - 2020-2021ESG report published
 1st Israeli E&P LP to publish
 - □ Update Code of Ethics published
- Adopting SDG's goals building inherent strategy.
- ☐ Working on a near term and long-term commitment strategy.
- Working on a near term and long-term detailed commitment roadmap.

NewMed's delegates at a hydrogen refueling station, "Green Planet", Pesse, NL.






P&L Summary (\$mm)


	Q1'22	Q1'21	2021
Revenues			
From natural gas and condensate sales	246,799	216,455	882,537
Net of royalties	36,043	32,164	128,758
Revenues, net	210,756	184,291	753,779
Expenses and costs:			
Cost of natural gas and condensate production	33,643	26,910	118,382
Depreciation, depletion and amortization expenses	37,750	21,034	113,083
Other direct expenses	995	766	4,206
G&A expenses	3,128	3,022	17,183
Total expenses and costs	75,516	51,732	252,854
The Partnership's share in the losses of a company accounted for at equity	(1,138)	(1,215)	(4,497)
Operating income	134,102	131,344	496,428
Financial expenses	(38,327)	(51,073)	(211,306)
Financial income	19,909	12,920	31,468
Financial expenses, net	(18,418)	(38,153)	(179,838)
Profit before taxes on income	115,684	93,191	316,590
Taxes on income	(31,638)	-	(207,837)
Income from continuing operations	84,046	93,191	108,753
Income from discontinued operations	-	21,548	151,736
Income from the sale of natural gas and oil assets	-	-	144,583
Total income from discontinued operations	-	21,548	296,319
Net profit	84,046	114,739	405,072



Financial Debt (\$mm)



Cash and Cash equivalent as of 31/03/2022 - \$315 mm



Dividend and Buy Back

- ☐ The partnership's BOD has decided on a Levithan Bond Buy Back plan of up to \$100mm for the outstanding notes.
- ☐ The partnership has declared a \$50mm profit distribution to unitholders





Appendix



Leviathan Bond Sponsor Financial Data Report

PERIOD ENDED <u>ITEM</u>	31.3.2022 <u>QUANTITY/ACTUAL</u> AMOUNT (IN USD\$,000)	
Total Offtake (BCM)	2.7	
Leviathan Revenues (100%)	544,550	
Loss Proceeds, if any, paid to Revenue Account	-	
Sponsor Deposits, if any, into Revenue Account	-	
Gross Revenues (before Royalties)	223,133	
Overriding Royalties		
(a) Statutory Royalties	(26,464)	
(b) Third Party Royalties	(10,496)	
Net Revenues	186,173	
Costs and Expenses:		
(a) Fees Under the Financing Documents (Interest Income)	24	
(b) Taxes	-	
(c) Operation and Maintenance Expenses	(30,715)	
(d) Capital Expenditures	(30,805)	
(e) Insurance (income)	-	
Total Costs and Expenses (sum of Items H(a), (b), (c), (d) and (e))	(61,496)	
Total Cash Flows Available for Debt Service (Item G minus Item H)	124,677	
Total Cash Flow from operation (Item G minus Items H(c) and H(e)	155,458	
Total Debt Service	-	
Total Distribution to the Sponsor	100,000	